Want to see AU:IIQ full AI Analyst Report?
IIQ Stock Chart & Stats
AU$0.40
AU$0.02(3.09%)
At close: 4:00 PM EST
AU$0.40
AU$0.02(3.09%)
Day’s Range― - ―
52-Week RangeAU$0.17 - AU$0.57
Previous CloseN/A
Volume76.26K
Average Volume (3M)196.06K
Market Cap
AU$23.23M
Enterprise ValueAU$67.66
Total Cash (Recent Filing)AU$13.80M
Total Debt (Recent Filing)AU$270.31K
Price to Earnings (P/E)―
Beta0.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,775,450
10 Day Avg. Volume262,451
30 Day Avg. Volume196,057
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.46
Price to Sales (P/S)22.67
P/FCF Ratio-8.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Diagnostics PlatformINOVIQ’s core focus on blood-based biomarker diagnostics and research tools addresses a durable healthcare need—earlier, more accurate detection in oncology and disease areas. This specialization supports recurring test demand, clinical adoption cycles and licensing opportunities over the medium term.
Diversified Monetisation StreamsMultiple revenue channels (product sales, research tools, collaborations, grants) provide structural flexibility. Diversified monetisation lets the company scale via partner deals and licensing, reducing single-stream reliance and improving resilience while commercial validation continues.
Low Financial LeverageVery low debt levels give INOVIQ a durable financial buffer and lower interest burden, preserving capacity to fund R&D and commercialization from equity or non-debt sources. This reduces solvency risk and provides runway relative to highly leveraged peers.
Bears Say
Declining RevenueSustained top-line decline undermines scale economics and weakens credibility with partners and customers. Falling revenue constrains reinvestment into validation and commercialisation, worsening cash runway and making it harder to achieve the volumes needed for durable profitability.
Negative ProfitabilityPersistent negative gross profit and operating margins indicate the core business is loss-making. Without meaningful margin recovery or material scale, the company cannot self-fund growth, forcing reliance on external capital and limiting long-term operational sustainability.
Negative Operating & Free Cash FlowOngoing negative operating and free cash flows erode reserves and increase dependence on external funding. Persistent cash burn raises refinancing and dilution risk and constrains R&D, clinical validation, and market rollout over the coming months until cash generation improves.
Inoviq Ltd News
IIQ FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest share price was AU$0.17 and its highest was AU$0.56 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is AU$23.23M.
When is Inoviq Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inoviq Ltd’s earnings last quarter?
Currently, no data Available
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in AU:IIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IIQ Sentiment 92%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth AU$13.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.77%
Trailing 12-Months
Company Description
Inoviq Ltd
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Technical Analysis
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Imagion Biosystems Ltd.
―